Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QP3P | ISIN: CA7736671008 | Ticker-Symbol:
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
ROCKLAND RESOURCES LTD Chart 1 Jahr
5-Tage-Chart
ROCKLAND RESOURCES LTD 5-Tage-Chart
ACCESSWIRE
313 Leser
Artikel bewerten:
(1)

Rockland Resources Ltd.: Rockland Resources Announces Board and Advisory Board Additions

Finanznachrichten News

VANCOUVER, BC / ACCESSWIRE / March 14, 2024 / Rockland Resources Ltd. (the "Company" or "Rockland") (CSE:RKL) is pleased to announce the appointment of Dr. Tom McCandless to its Board of Directors and Mackenzie (Mac) Watson to the Advisory Board.

"We are pleased to welcome Tom and Mac to the growing team at Rockland. Their combined knowledge and experience in the mining space will greatly enhance our chances of success in the exploration stage of our various projects," stated Mike England, CEO of Rockland Resources.

Dr. McCandless has over 40 years of experience in mineral discovery and development over a broad range of commodities including lithium, uranium, gold, base metals, PGE, and geothermal energy. Most recently he served as Vice President of Exploration for Mountain Province Diamonds, overseeing exploration of their joint venture share at the world-class Gahcho Kué Diamond Mine, and for their Kennady North Project surrounding the mine. Since 2008 he is the President of MCC Geoscience Inc. and has consulted for grassroots exploration through to operating mines located in North and South America, Africa, and Europe. He is also a registered professional geoscientist (BC, NT/NU) and an Adjunct Professor at the University of Alberta and University of Arizona.

Mr. Watson, B.Sc., P.Eng., has over 50 years of experience in exploration, finance, development, and operations in the mining industry. Mr. Watson has spent his career in the junior mining sector, notably serving as Chief Executive Officer (CEO) of Lynx Canada Exploration Ltd. until 1985, then as CEO for Freewest Resources Inc. until its acquisition by Noranda in 1994. He then served as CEO of Freewest Resources Canada Inc. until its acquisition by Cliffs Natural Resources in 2010. Mac is the first person to receive the Bill Dennis Award for a Canadian Discovery and/or prospecting success twice: first in 1991 for numerous discoveries, and again in 2009 as part of the team responsible for chromite discoveries in the Ring of Fire. He also holds the Quebec Prospector of the Year Award in 1992 for his participation in the discovery of the Pusticamica and Verneuil gold deposits in Quebec. In January 2015, Mr. Watson was inducted into the Canadian Mining Hall of Fame.

The Company further announces it has arranged a non-brokered private placement of 2 million units ("Units") at a price of $0.025 per Unit for aggregate gross proceeds of $50,000.00 (the "Offering"). Each Unit will be comprised of one common share ("Share") and one-half transferable Share purchase warrant of the Company ("Warrant"). Each whole Warrant will entitle the Subscriber to purchase one Warrant Share for a 24-month period after the Closing Date at an exercise price of $0.05 per share. Proceeds raised from the Offering will be used for general and administrative purposes.

Rockland also announces it has set 2,000,000 options to directors, officers and consultants of the company at an exercise price of $0.05 cents for a period of three years in accordance with the company's stock option plan.

About Rockland Resources Ltd.

Rockland Resources is engaged in the business of mineral exploration and the acquisition of mineral property assets for the benefit of its shareholders.

On Behalf of the Board of Directors
Michael England, CEO & Director

For further information, please contact:
Mike England
Email: mike@engcom.ca

Neither the Canadian Stock Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS: This news release contains forward-looking statements, which relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at WWW.SEDAR.COM).

SOURCE: Rockland Resources Ltd.



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.